• Study of carboplatin, paclitaxel, and tislelizumab treatment in patients with resectable locally advanced oral cavity squamous cell carcinoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Italy

  • A study of futibatinib combined with tislelizumab, fluorouracil, calcium folinate, and oxaliplatin as first-line treatment for patients with colorectal cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Germany

  • Study of Remternetug for Prevention of Disease Progression in People at Risk for or With Early Onset Inherited Alzheimer’s Disease

    Recruiting

    4 1
    Investigated Diseases:
    Investigated Drugs:
    France Germany Italy The Netherlands Spain

  • Study of MK-1084, cetuximab and mFOLFOX6 combination compared to mFOLFOX6 with or without bevacizumab for patients with KRAS G12C-mutant advanced colorectal cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Finland France Germany Hungary Italy The Netherlands +3

  • Comparing two forms of mupirocin (gel and ointment) for treating impetigo in children: a study of different dosing schedules

    Recruiting

    3 1 1 1
    Spain

  • Study of ABBV-453 alone or with drug combination for adults with multiple myeloma: evaluation of safety and effectiveness

    Recruiting

    1 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Belgium France Germany Italy Poland Portugal +1

  • Study of mirvetuximab soravtansine dosing schedules for patients with platinum-resistant advanced ovarian, peritoneal, or fallopian tube cancer with high folate receptor expression

    Recruiting

    2 1 1 1
    Investigated Drugs:
    Belgium France Poland Spain

  • Study of sonrotoclax plus obinutuzumab or rituximab compared to venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

    Recruiting

    3 1 1 1
    Investigated Drugs:
    Austria Belgium Czechia Denmark France Germany +6

  • A study of Pseudovax, molgramostim and tislelizumab combination therapy for patients with pseudomyxoma peritonei cancer

    Recruiting

    1 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Norway

  • Study of trastuzumab deruxtecan with bevacizumab versus bevacizumab alone as first-line maintenance treatment for patients with HER2-expressing ovarian cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    Austria Belgium Bulgaria Czechia Denmark France +8

powered by